Focused On-demand Library for WD repeat-containing protein 36

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8NI36

UPID:

WDR36_HUMAN

Alternative names:

T-cell activation WD repeat-containing protein

Alternative UPACC:

Q8NI36; A2RUS4; Q68E02; Q8N1Q2

Background:

WD repeat-containing protein 36, also known as T-cell activation WD repeat-containing protein, plays a crucial role in the small subunit (SSU) processome, contributing to the assembly of the first precursor of the small eukaryotic ribosomal subunit. It is involved in the nucleolar processing of SSU 18S rRNA, facilitating RNA folding, modifications, rearrangements, and cleavage. Additionally, this protein is pivotal in T-cell activation and is highly coregulated with IL2.

Therapeutic significance:

Given its involvement in primary open angle glaucoma (POAG), a condition characterized by optic nerve damage and visual field defects, WD repeat-containing protein 36 represents a promising target for therapeutic intervention. Understanding the role of WD repeat-containing protein 36 could open doors to potential therapeutic strategies.